Pfizer Goodwill and Intangible Assets 2010-2024 | PFE
Pfizer goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Pfizer goodwill and intangible assets for the quarter ending June 30, 2024 were $129.685B, a 39.48% increase year-over-year.
- Pfizer goodwill and intangible assets for 2023 were $132.683B, a 40.04% increase from 2022.
- Pfizer goodwill and intangible assets for 2022 were $94.745B, a 27.42% increase from 2021.
- Pfizer goodwill and intangible assets for 2021 were $74.354B, a 4.54% decline from 2020.
Pfizer Annual Goodwill and Intangible Assets
(Millions of US $) |
| 2023 |
$132,683 |
| 2022 |
$94,745 |
| 2021 |
$74,354 |
| 2020 |
$77,893 |
| 2019 |
$82,138 |
| 2018 |
$88,622 |
| 2017 |
$104,693 |
| 2016 |
$107,097 |
| 2015 |
$88,598 |
| 2014 |
$77,235 |
| 2013 |
$81,904 |
| 2012 |
$88,807 |
| 2011 |
$95,753 |
| 2010 |
$101,483 |
| 2009 |
$110,391 |
Pfizer Quarterly Goodwill and Intangible Assets
(Millions of US $) |
| 2024-06-30 |
$129,685 |
| 2024-03-31 |
$132,126 |
| 2023-12-31 |
$132,683 |
| 2023-09-30 |
$91,751 |
| 2023-06-30 |
$92,978 |
| 2023-03-31 |
$93,478 |
| 2022-12-31 |
$94,745 |
| 2022-09-30 |
$77,592 |
| 2022-06-30 |
$78,956 |
| 2022-03-31 |
$80,027 |
| 2021-12-31 |
$74,354 |
| 2021-09-30 |
$75,795 |
| 2021-06-30 |
$77,190 |
| 2021-03-31 |
$77,765 |
| 2020-12-31 |
$77,893 |
| 2020-09-30 |
$90,829 |
| 2020-06-30 |
$91,990 |
| 2020-03-31 |
$92,966 |
| 2019-12-31 |
$82,138 |
| 2019-09-30 |
$97,660 |
| 2019-06-30 |
$86,376 |
| 2019-03-31 |
$87,526 |
| 2018-12-31 |
$88,622 |
| 2018-09-30 |
$100,920 |
| 2018-06-30 |
$102,420 |
| 2018-03-31 |
$104,083 |
| 2017-12-31 |
$104,693 |
| 2017-09-30 |
$105,799 |
| 2017-06-30 |
$106,362 |
| 2017-03-31 |
$107,083 |
| 2016-12-31 |
$107,097 |
| 2016-09-30 |
$110,519 |
| 2016-06-30 |
$93,656 |
| 2016-03-31 |
$88,160 |
| 2015-12-31 |
$88,598 |
| 2015-09-30 |
$90,514 |
| 2015-06-30 |
$74,995 |
| 2015-03-31 |
$76,188 |
| 2014-12-31 |
$77,235 |
| 2014-09-30 |
$79,098 |
| 2014-06-30 |
$80,021 |
| 2014-03-31 |
$80,589 |
| 2013-12-31 |
$81,904 |
| 2013-09-30 |
$82,949 |
| 2013-06-30 |
$84,207 |
| 2013-03-31 |
$87,861 |
| 2012-12-31 |
$88,807 |
| 2012-09-30 |
$91,579 |
| 2012-06-30 |
$92,967 |
| 2012-03-31 |
$98,053 |
| 2011-12-31 |
$95,753 |
| 2011-09-30 |
$101,006 |
| 2011-06-30 |
$102,166 |
| 2011-03-31 |
$103,350 |
| 2010-12-31 |
$101,483 |
| 2010-09-30 |
$102,414 |
| 2010-06-30 |
$105,373 |
| 2010-03-31 |
$107,128 |
| 2009-12-31 |
$110,391 |
| 2009-09-30 |
$37,921 |
| 2009-06-30 |
$38,405 |
| 2009-03-31 |
$38,405 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$168.584B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
